Eisai Inc. announced that it will present new data for FYCOMPA® (perampanel) CIII, including FREEDOM study results and the final results of one of the pediatric studies that supported the FDA approval for partial-onset seizures in patients as young as 4 years, at the upcoming 33rd International Epilepsy Congress (IEC) taking place on June 22-26, in Bangkok, Thailand.
June 13, 2019
· 17 min read